Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Wegovy (semaglutide) and Ozempic (semaglutide) are both GLP-1 receptor agonists used to lower the risk of heart attack, stroke, and death due to heart problems in adults with heart disease. Both can result in weight loss, but, they have different FDA-approved uses. Wegovy is approved for long-term weight management in adults and children aged 12 and older living with overweight or obesity, while Ozempic is approved for treating Type 2 diabetes in adults. Both medications are injected under the skin once a week, but the dosing schedules differ. Common side effects for both include nausea, diarrhea, and stomach pain. Additionally, both medications carry risks of thyroid cancer, pancreatitis, and gallbladder problems, and should not be used if you have a history of certain thyroid cancers or are allergic to semaglutide.
Wegovy (semaglutide)
Ozempic (semaglutide)
Wegovy (semaglutide)
Ozempic (semaglutide)
Summary of Wegovy vs. Ozempic
Summary for GLP-1 agonist
Prescription only
Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It comes in prefilled pens you use to inject the medication under the skin once a week. Wegovy (semaglutide) also comes as tablets that are swallowed once a day. This medication is approved for weight loss in some people. It can help lower the risk of heart attack, stroke, and death due to heart problems in adults with a larger body size and heart disease. The pens are also approved for certain adults with a liver problem called metabolic dysfunction-associated steatohepatitis (MASH). The medication works best when taken with a lower-calorie diet and regular exercise. Side effects include nausea, diarrhea, and stomach pain.
Summary for GLP-1 agonist
Prescription only
Ozempic (semaglutide) is a prescription injection used with diet and exercise to help manage Type 2 diabetes in adults. It's also FDA approved to lower the risk of heart attack, stroke, and heart-related death in those with Type 2 diabetes and heart disease. In addition, it can reduce the risk of worsening kidney problems in people with Type 2 diabetes and chronic kidney disease (CKD). Ozempic (semaglutide) is a GLP-1 agonist that's injected under the skin once a week. Common side effects include nausea, vomiting, and diarrhea.